Open AccessProphylactic colchicine therapy of intercritical gout. A placebo‐controlled study of probenecid‐treated patients
Author(s) -
Paulus Harold E.,
Schlosstein Lee H.,
Godfrey Robert G.,
Klinenberg James R.,
Bluestone Rodney
Publication year - 1974
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.1780170517
Subject(s) - colchicine , gout , probenecid , medicine , hyperuricemia , placebo , acenocoumarol , uric acid , warfarin , alternative medicine , pathology , atrial fibrillation
The serum urate‐lowering effect of probenecid was used to monitor compliance in a placebo‐controlled study of prophylactic colchicine therapy for intercritical gout. Although all patients included in the analysis had satisfactory control of hyperuricemia, 20 patients receiving 1.5 mg of colchicine daily averaged 2.3 attacks of acute gout per year of therapy, compared to 18 placebo‐treated patients who averaged 6 attacks per year (P < 0.05), confirming the effectiveness of prophylactic colchicine in this situation.